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Abstract
Purpose: The in vivo evaluation of three modified polyethylene glycol (PEG)-anilinoquinazoline
derivatives labeled with
124I,
18F, and
11C as potential positron emission tomography (PET)
bioprobesforvisualizingepidermalgrowthfactorreceptor(EGFR)incancerusingsmallanimalPET.
Procedures: Xenograft mice with the human glioblastoma cell lines U138MG (lacking EGFR
expression) and U87MG.wtEGFR (transfected with an overexpressing human wild-type EGFR
gene) were used. Static and dynamic PET imaging was conducted for all three PEGylated
compounds. Tumor necrosis, microvessel density, and EGFR levels were evaluated by
histopathology and enzyme-linked immunosorbent assay.
Results: Nineteen animal models were generated (two U138MG, three U87MG, 14 with both
U138MG and U87MG bilateral masses). In static images, a slight increase in tracer uptake was
observed in tumors, but in general, there was no retention of tracer uptake over time and no
difference in uptake between U138MG and U87MG masses. In addition, no significant uptake
was demonstrated in dynamic scans of the
18F-PEG tracer. No necrosis was present except in
four animals. MVD was 9.6 and 48 microvessels/×400 field in the U138GM and U87GM masses,
respectively (p=0.00008). Similarly, the microvessel grades were generally higher in the U87GM
group (p=0.002). Total EGFR amount was higher in U87MG than U138MG masses (p=0.001),
but the ratio of activated (pY1068) to total EGFR did not differ (p=0.95).
Conclusions: PEGylated tracers labeled with
11C,
124I, and
18F showed no significant difference in
uptake between U138MG and U87MG glioblastoma xenograft mice. The tracer binding with EGFR
could be influenced by activation of the tyrosine kinase portion of the receptor which was similar in
U138MG and U87MG. Despite these results, these tracers should be investigated in animal models
withmutantEGFRgenestodeterminewhetheraberrantreceptorfunctionplaysaroleintumoruptake.
Key words: Epidermal growth factor receptor (EGFR), Small animal PET, Tyrosine kinase (TK)
inhibitors
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T
he epidermal growth factor receptor tyrosine kinase
(EGFR-TK) is currently considered one of the most
interesting molecular targets for cancer therapy [1]. EGFR is
differentially dysregulated, overexpressed, mutated, or
amplified in many types of cancer, and this may be
associated with more aggressive disease, therapy resistance,
and shorter survival time [2–5]. Two major therapeutic
strategies have been developed to inhibit EGFR pathways in
cancer: monoclonal antibodies (Abs) that target the external
binding domain (ligand binding domain) of the receptor or
small molecular weight inhibitors that target the intracellular
TK domain [6]. Some molecular markers for selecting
patients who may benefit from these drugs and predict
response to EGFR-targeted therapy are under investigation.
Thus, an attempt to quantify EGFR in tumors in vivo has
become one of the most pressing challenges in cancer
research.
Different imaging approaches have been devised for
EGFR detection, ranging from optical imaging modalities
to single photon emission computed tomography and
positron emission tomography (PET) technologies [7]. New
PET probes, including labeled monoclonal Abs and small
molecules such as TK inhibitors, have been developed and
evaluated in the preclinical setting for EGFR visualization
[8–25]. Although most of these TK inhibitor tracers showed
promising and potential characteristics in vitro, none of them
proved successful in the clinical setting. The main draw-
backs of these EGFR PET agents stem from their rapid
clearance from blood, moderate and nonspecific binding in
tumors, and high accumulation in metabolic organs. To
overcome these limitations, a newer generation of labeled
irreversible EGFR inhibitors was developed [26, 27]. This
group of compounds contains a polyethylene glycol (PEG)
group at the 7-position of the quinazoline ring to increase
solubility and decrease (logP) and a dimethylcrotonylamide
at the 6-position to form covalent binding with the receptor.
These compounds were labeled either with carbon-11 on the
dimethylamine moiety (
11C-1), fluorine-18 on the F-PEG
moiety (
18F-2), or iodine-124 at the anilino moiety (
124I-3;
Fig. 1). Herein, we report the micro-PET results of three of
these compounds in tumor-bearing mice.
Materials and Methods
Cells
Two human glioblastoma cell lines were used: U138MG lacks
EGFR (HER-1) expression, whereas U87MG.wtEGF-R (U87MG)
was transfected with an overexpressing human wild-type EGFR
gene [17]. Cells were routinely cultured in DMEM supplemented
with 10% fetal bovine serum and were maintained at 37°C in a
humidified 5% CO2 atmosphere. The U87MG cells were also
routinely supplemented with G418 at a final concentration of
500 μg/ml. All medium constituents were purchased from
Invitrogen, Milan, Italy.
Cytofluorometric Studies
Glioblastoma cell line phenotype was studied by means of indirect
immunofluorescence and cytofluorometric analysis. The following
primary mouse monoclonal antibodies were used: antihuman HER-
1 (EGF-R) clone 528 (Oncogene Research Products, Uniondale,
NY, USA), antihuman HER-2 clone MGR-3, and antihuman HER-
3 clone SGP1 (NeoMarkers, Fremont, CA, USA). The secondary
antibody was Alexa Fluor 488 F(ab’)2 fragment of goat antimouse
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Fig. 1. Chemical structure of the
11C-1,
18F-2, and
124I-3
compounds.
M. A. Pantaleo, et al.: Molecular Imaging of EGFR in Cancer 617IgG (Invitrogen, Milan, Italy). After the final washings, cells were
resuspended in phosphate-buffered saline containing 1 μg/ml of
ethidium bromide to gate out dead cells followed by cytofluoro-
metric analysis with a FACScan (Becton Dickinson, St. Jose, CA,
USA).
Mice
Athymic Crl:CD-1-Foxn1
nu/nu mice (here referred to as nude mice)
were purchased from Charles River Italy and kept under sterile
conditions. Experiments were authorized by the institutional review
board of Bologna University and performed according to Italian
and European guidelines.
U138MG and U87MG cells (3×10
6 and 5×10
6, respectively)
were injected subcutaneously (s.c.) in the hind legs. Mice carrying
a single tumor derived from a subcutaneous injection of each cell
line or carrying both tumors (one on each side) were obtained.
Tumor incidence and growth were evaluated weekly. Neoplastic
masses were measured with calipers; tumor volume was calcu-
lated as π×[√(a×b)]
3/6, where a = maximal tumor diameter and
b = a tumor diameter perpendicular to a. Animals underwent PET
imaging 5–6o r1 0 –15 days after cell injection. At sacrifice, tumor
samples were mechanically and enzymatically dissociated using
Trypsin–EDTA to obtain a single cell suspension for evaluation
of EGFR expression by cytofluorometric analysis. Additional
samples for histological determinations and biomolecular studies
were fixed in 10% phosphate-buffered formalin or frozen in liquid
nitrogen.
Chemistry
The labeled compounds were prepared according to recent
publications [26, 27].
Imaging Protocol
The PET imaging procedure was as follows: Mice were anesthe-
tized (Sevofluorane 3–5% and oxygen 1 lmin
−1) and injected with
variable doses of tracers (ranging from 10 to 37 MBq according to
the isotope half-life) with an insulin syringe via the tail vein. All
animals were evaluated in a static mode. This approach was chosen
since the primary aim of this work was to evaluate tracer uptake
related to the EGFR expression. Two animals injected with
18F-2
underwent dynamic scans to evaluate whether an early tracer
uptake and a later washout were present.
For static acquisitions (repeated several times after injection to
monitor tracer distribution), animals were subsequently allowed to
awaken and move freely for the uptake period. Finally, anesthesia
was induced a second time before the animal was placed prone on
the scanner bed of the small animal PET tomograph (GE, eXplore
Vista DR). Imaging lasted at least 15 min per bed position.
For dynamic acquisitions, the animal was anesthetized, placed
prone on the scanner bed, centered in the field of view, and then
injected intravenously with the tracer. Simultaneously, the dynamic
list mode acquisition was started. Image acquisition lasted for
30 min.
Since the axial field of view was only 4 cm, one bed position
was not sufficient to cover the whole body. Therefore, a group of
animals underwent at least one static whole body scan (two bed
positions) to verify the whole body distribution of the tracer. For
the remaining animals, images were acquired on tumor areas only.
Once the scan had been completed, gas anesthesia was interrupted
and the animal was placed in a warm recovery box.
The images were reconstructed with iterative reconstruction 2D
OSEM, matrix 175×175. Due to the small size of the animals, we
did not apply attenuation correction or scatter correction as they do
not significantly influence semiquantitative PET analysis since
t h ev e r yh i g he n e r g yo ft h ee m i t t e dp h o t o n s( 5 1 1K e V )l e dt oa
very high rate of nonabsorbed photons. Using this system, the
Table 1. Image acquisition features for
124I-3
Cell line Uptake time FOV Static Dynamic Necrosis
1 Control, no tumor 60 min, 24 h, 48 h WB Yes No No
2 U138MG 60 min, 4 h WB Yes No No
3 U138MG 60 min, 5 h WB Yes No No
4 U87MG 60 min, 24 h WB Yes No No
5 U87MG 60 min, 5 h WB Yes No No
6 U87MG 60 min, 4 h, 24 h, 48 h WB Yes No No
7 U87MG + U138MG 20 min, 2 h, 5 h, 24 h, 48 h WB Yes No No
8 U87MG + U138MG 60 min, 18 h, 39 h Segm Yes No No
9 U87MG + U138MG 60 min, 18 h, 39 h Segm Yes No No
10 U87MG + U138MG 24 h, 36 h Segm Yes No No
11 U87MG + U138MG 60 min, 24 h, 36 h Segm Yes No No
U138MG (EGFR−) cell line, U87MG (EGFR+) cell line, WB whole body acquisition, Segm segmental acquisition
Table 2. Image acquisition features for
18F-2
Cell line Uptake time (min) FOV Static Dynamic Necrosis
1 U87MG + U138MG 5, 60, 150 Segm Yes No Yes
2 U87MG + U138MG 5, 60, 150 Segm Yes No Yes
3 U87MG + U138MG 5, 60, 150 Segm Yes No Yes
4 U87MG + U138MG 5, 60, 150 Segm Yes No Yes
5 U87MG + U138MG 60, 120 Segm Yes Yes (30 min) No
6 U87MG + U138MG 60, 120 Segm Yes Yes (30 min) No
U138MG (EGFR−) cell line, U87MG (EGFR+) cell line, WB whole body acquisition, Segm segmental acquisition
618 M. A. Pantaleo, et al.: Molecular Imaging of EGFR in Cancerbest attainable spatial resolution was 1.4 mm as described by
Wang et al. in their performance evaluation [20]. According to
this procedure, the image quality was satisfactory for all of the
scans. Although the image quality could have been slightly
improved especially by increasing the acquisition time, as in
every nuclear medicine test, it was unnecessary since a prolonged
acquisition time reduces the number of scanned animals per tracer
synthesis.
For static acquisitions, a semiquantitative analysis was per-
formed by calculating the tumor-to-background ratio (TBR) on the
pelvic area of increased uptake. TBR was calculated as follows:
TBR ¼ Max Count in the Target Region of Interest ROI ðÞ =
Mean Count in the Background ROI
The background ROI was drawn on the subcutaneous tissues.
For dynamic acquisitions, a ROI was drawn on the tumor and a
time/activity curve was generated. No correction for decay was
applied.
124I-3
Eleven animals underwent PET imaging with 10 to 30 MBq of the
iodinated tracer. Three animals also underwent a small animal CT
whole body acquisition that was used for accurate localization of
activity uptake detected by the micro-PET. Table 1 shows the
animal population and the image acquisition features.
18F-2
Six animals underwent PET imaging with approximately 37 MBq
of the fluorinated tracers. Table 2 shows the animal population and
the image acquisition features.
11C-1
Three animals underwent PET imaging with approximately
37 MBq of the carbon-11 tracer. Table 3 shows the animal
population and the image acquisition features.
Molecular and Pathological Analyses
After sacrifice, tumor necrosis, microvessel density (MVD)
analysis, and total and activated (pY1068) EGFR quantification
were evaluated. Immunostains were adopted to evaluate endothelial
cells. Anti-CD31 antibody (Santa Cruz, CA, USA) at a 1:20
dilution was used. The sections underwent antigen retrieval in
EDTA (pH=6.0) in a microwave at 750 W (four cycles lasting
5 min each) and revealed by the alkaline phosphatase–anti-alkaline
Table 3. Image acquisition features for
11C-1
Cell line Uptake time (min) FOV Static Dynamic Necrosis
1 U87MG + U138MG 10 Segm Yes No No
2 U87MG + U138MG 10 Segm Yes No No
3 U87MG + U138MG 10 Segm Yes No No
U138MG (EGFR−) cell line, U87MG (EGFR+) cell line, WB whole body acquisition, Segm segmental acquisition
Table 4. Imaging results for all tested tracers
Cell line Tracer Uptake time TBR EGFr+ TBR EGFr−
1 Control 124I-3 60 min, 24 h, 48 h ––
2 U138MG 124I-3 60 min, 4 h – G1
3 U138MG 124I-3 60 min, 5 h – G1
4 U87MG 124I-3 60 min, 24 h G1, G1 –
5 U87MG 124I-3 60 min, 5 h G1, G1 –
6 U87MG 124I-3 60 min, 4 h, 24 h, 48 h G1, G1, G1, G1 –
7 U87MG + U138MG 124I-3 20 min, 2 h, 5 h, 24 h, 48 h G1, G1, G1, G1, G1 G1, G1, G1, G1, G1
8 U87MG + U138MG 124I-3 60 min, 18 h, 39 h G1, G1, G1 G1, G1, G1
9 U87MG + U138MG 124I-3 60 min, 18 h, 39 h G1, G1, G1 G1, G1, G1
10 U87MG + U138MG 124I-3 24 h, 36 h – 2.1, 4
11 U87MG + U138MG 124I-3 60 min, 24 h, 36 h –, 1.1, 4 –, 2.7, 5.1
12 U87MG + U138MG 18F-2 5 min, 60 min, 150 min G1, G1, 1.2 G1, G1, 1
13 U87MG + U138MG 18F-2 5 min, 60 min, 150 min G1, 1.5, 1.3 G1, 1.5, 1.1
14 U87MG + U138MG 18F-2 5 min, 60 min, 150 min 1.6, 1.6, G1 1.5, 1.5, G1
15 U87MG + U138MG 18F-2 5 min, 60 min, 150 min 1.2, 1.6, 1 G1, 1, 1.2
16 U87MG + U138MG 18F-2 60 min, 120 min 1.1, 2.6 1.8, 2.4
17 U87MG + U138MG 18F-2 60 min, 120 min 1.8, 1.4 2.8, 1.2
18 U87MG + U138MG 11C-1 10 min 1.7 1.7
19 U87MG + U138MG 11C-1 10 min 4.3 3.3
20 U87MG + U138MG 11C-1 10 min 1.6 1.6
Ten out of 20 animals presented a tumor-to-background ratio of ≤1 in U138MG and U87MG masses (the tracer uptake was very limited and did not
significantly differ from subcutaneous tissues). The remaining ten masses presented a tumor-to-background ratio ≥1 (some animals had an increasing uptake
while others had a decreasing trend over time)
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estimate MVD. In the first method, visual microvessel grading,
the slides were visually scanned at ×100, ×200, and ×400
magnification and semiquantitatively graded for the extent of
CD31 staining. To ensure the accuracy of the grading method,
each sample was reviewed by two observers. Morphologic analysis
was performed carefully to ensure vessel specificity of the CD31-
stained stroma considered for the analysis. Four different micro-
vessel grades (MVG) were considered as previously described [28]:
MVG 1, normal or slightly increased MVD; MVG 2, microvessels
easy to detect and definitely increased in respect to normal; MVG
3, abundant microvessels; and MVG 4, strongly increased MVD.
Nonneoplastic human nervous tissues were used as control
reference. The second method, visual count, involved counting
microvessels according to previously described methods [28, 29].
In performing this visual count, each of the slides was first scanned
at ×100 magnification, and three areas with abundant microvessels
were chosen and defined as “hot spots”. The number of micro-
vessels in each of these hot spots was then determined at ×400
magnification. The final MVD number was determined by taking
the average of the three separate visual counts. During counting,
vessels in the tumor capsule were excluded. Areas of staining with
no discrete breaks were counted as single vessels, and the presence
of a lumen was not required.
The two-tailed Student T test was used to compare U87GM and
U138GM mice. Differences were considered significant for p
valuesG0.05. Pearson’s correlation was used to compare MVD and
MVG methods.
Total and activated (pY1068) EGFR quantification was per-
formed using an enzyme-linked immunosorbent assay (ELISA).
For protein extraction, frozen tissues were homogenized using lysis
buffer (50 mM Tris, pH7.4, 150 mM NaCl, 2 mM MgCl2,1 %
Triton X-100, 10% glycerol, 2 mM EGTA, 1 mM DTT) containing
protease inhibitors (10 mg ml
−1 aprotinin and leupeptin, 5 mg ml
−1
pepstatin, 1 mM phenylmethylsulfonyl fluoride) and phosphatase
inhibitors (50 mM NaF, 10 mM Na4P2O7, 1 mM Na3VO4,3m M
H2O2). Homogenates were centrifuged at 13,000×g for 15 min at
4°C, and supernatants were stored at −80°C until analysis. Total
and activated EGFR concentrations were assessed using ELISA kits
purchased from Biosource International Inc. (Camarillo, CA, USA).
Relative activated (pY1068) EGFR was defined as pY1068/total
EGFR.
Results
Animal Model Development
The human glioblastoma cell lines U138MG (lacking EGFR
expression) and U87MG (transfected with an overexpressing
human wild-type EGFR gene) were used to establish a
subcutaneous xenograft tumor model in nude mice for the
assessment of EGFR labeling with innovative PET biop-
robes. Indirect immunofluorescence and cytofluorometric
analyses were used to study the growth factor receptor
expression profile of EGFR (HER-1) and HER/erbB family
receptors HER-2 and HER-3 in U138MG and U87MG cells.
As indicated by the cytofluorometric profile, U87MG cells
in continuous culture showed EGFR overexpression on the
cell surface, whereas U138MG cells were negative for
EGFR membrane expression. Surface expression of HER-2
Fig. 2. PET/CT images of an animal carrying a U87MG (EGFR+) tumor, 4 h after the tracer injection. The image fusion between
the CT and the PET image shows no specific tracer uptake in the tumor of
18F-2.
Fig. 3. The segmental
11C-1 static acquisition image (10 min
after the tracer injection) does not show any visual significant
difference between U87MG (EGFR+) and U138MG (EGFR−)
mass tracer uptake. TBR turned out to be 1.7 for both
masses.
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3 was expressed only in the U138MG cell line. When the
cell lines were grown as subcutaneous tumors in nude mice,
the HER/erbB family receptor expression profile was similar
to that seen when the cells were grown in continuous liquid
culture. Most importantly, EGFR expression in U87MG
xenografts remained very high, whereas U138MG xeno-
grafts remained completely negative for EGFR expression.
The xenograft tumor model was established by s.c.
injection of 3×10
6 U138MG or 5×10
6 U87MG cells into
the hind legs of nude mice. After subcutaneous injection,
tumor growth became evident after a median latency time
of 4 days for both cell lines. U138MG tumor growth was
exponential whereas U87MG growth was very slow and
sometimes indolent. However, no differences in tumor
latency, incidence, or growth were seen in mice carrying
one subcutaneous tumor or both (one on each hind leg).
Tumor-bearing animals underwent PET analysis 5 to
6 days after cell injection when tumor dimensions were
0.161±0.011 and 0.104±0.004 cm
3 for U138MG and
U87MG, respectively (dimensions from one experiment
representative of other similar experiments). PET analysis
was also performed 10–15 days after cell injection when
tumor dimensions were 3.368±0.956 and 0.785±
0.309 cm
3, respectively (dimensions from one experiment
14 days after cell injection representative of other similar
experiments).
Tumor Uptake
The time elapsed between the injection of the tracers and
image acquisition is listed in Tables 1, 2, 3, and 4. Table 4
shows the results of the static imaging procedures with the
tumor-to-background ratio. Some tumors presented a slight
increase in tracer uptake, but in general, there was no
retention over time and no significant difference between
U138MG and U87MG masses. Static acquisitions and
dynamic scans with the tested tracers showed no statistically
significant differences between tumor xenografts (Figs. 2, 3,
and 4). Dynamic scans did not demonstrate any significant
uptake of
18F-2 over time (Fig. 5).
Molecular and Pathological Analyses
No necrosis was present except in four animals with bilateral
tumors where it was found both in U87MG and U138MG
masses because of high tumor size. Results from the two
angiogenesis evaluation methods were absolutely compara-
ble (Pearson correlation, r=0.88). Moreover, there was a
very high interobserver consensus with more than 95%
agreement. Median MVD was 28.5 microvessels/×400 field
(range 6–70.8) in tumor samples and six microvessels/×400
field (range, 4–6) in nonneoplastic tissues. When the two
tumor xenografts were compared, mean MVD was 9.6 and
48 microvessels/×400 field in the U138GM and U87GM
masses, respectively (p=0.00008; Fig. 6). Similarly, the
Fig. 4. The segmental
18F-2 static acquisition image (5, 60,
and 150 min after the tracer injection) does not show visual
significant difference between U87MG (EGFR+) and U138MG
(EGFR−) mass tracer uptake. The cold area indicated by the
solid arrow in the U138MG EGFR− mass is related to
necrosis.
M. A. Pantaleo, et al.: Molecular Imaging of EGFR in Cancer 621MVG scores were generally higher in the U87GM group
(p=0.002). Total EGFR amount was higher in U87MG than
U138MG masses (p=0.001), but the ratio of activated
(pY1068) to total EGFR did not differ (p=0.95; Fig. 7).
Discussion
The present study reports on the development of PEG-
anilinoquinazoline derivatives labeled with
11C,
124I, and
18F
as potential probes for in vivo imaging of EGFR in U138MG
and U87MG glioblastoma xenograft mice using small
animal PET. The most important chemical features of these
PEGylated compounds were increased stability and solubil-
ity and decreased lipophilicity which together may increase
specific tracer uptake in tumors. In vitro studies showed that
these PEGylated derivative compounds had a high and
irreversible potency to inhibit EGFR autophosphorylation
[26, 27]. However, the in vivo imaging protocol of
11C-1,
18F-2, and
124I-3 showed only a slight increase in uptake in
some tumors and no significant difference between
U138MG and U87MG glioblastoma xenograft mice. The
lack of specific tumor uptake of these tracers could be due to
factors such as the target status in vivo, nonselective binding,
and their metabolism in vivo.
The molecular quantification of total EGFR by ELISA
differed between U138MG and U87MG tumor mass, but no
significant differences were found when the ratio of
activated/total EGFR was measured. Thus, tracer binding
to EGFR could be influenced by the activation of the
tyrosine kinase domain of the receptor which was similar in
U138MG and U87MG.
Though nonselective binding of tracers to other proteins
could reduce EGFR-specific uptake, this hypothesis is
unlikely. A higher affinity and selectivity of
11C-1 and
18F-
2 to EGFR compared to other tyrosine kinases (ERBB2,
IGF1R, KIT, PDGFRA, PDFGRB, VEGFR1, VEGFR2,
VEGFR3) has been described [26, 27]. The same results
were obtained for
124I-3 (unpublished data; Table 5).
However, these compounds may bind to targets other than
tyrosine kinase receptors, thus influencing their uptake.
Future genomic and proteomic studies of tumor masses
and cell cultures could be designed to define the molecular
background of these models. As U138MG and U87MG are
known to have different proliferation and growth rates in
mice, different molecular pathways may be up- and down-
regulated in vivo.
Fig. 5. The segmental
18F-2 static acquisition image (60 min after the tracer injection) does not show any visual significant
difference between U87MG (EGFR+) and U138MG (EGFR−) mass tracer uptake. TBR turned out to be G1 for both masses. The
two time-activity curves do not reveal any specific uptake.
Fig. 6. Micro vessel density evaluation in U87MG (EGFR+)
and U138MG (EGFR−) masses.
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influenced the results since all animals had a small mass at
the time of scan acquisition and no necrosis, except for four
animals with large bilateral necrotic tumors. Moreover,
MVD data showed that angiogenesis was more apparent in
U87GM tumors, suggesting sufficient tracer access to tumor
masses.
Although the results of the present study showed no
specific tumor uptake in micro-PET images for
11C-1,
18F-2,
and
124I-3, the promising in vitro characteristics of these
compounds merit further investigation in other animal
models. Cell lines characterized by both high receptor
expression and activation are deemed ideal for in vivo
imaging of EGFR tumors. Pal et al. reported the first in vitro
and in vivo studies of a morpholino-
124I-IPQA TK irrever-
sible inhibitor with a chemical structure allowing covalent
binding only to the ATP site of the phosphorylated EGFR-
TK in xenograft mice with brain tumors expressing
EGFRvIII mutant receptor [18]. Recently, Memon et al.
reported a higher uptake of
11C-Iressa in HCC827 xenograft
mice which overexpress a mutant EGFR harboring an in-
frame deletion mutation in exon 19 that likely confers a
constitutive activation to the receptor and erlotinib sensitiv-
ity compared with nonmutant A549 and NCI358 cell lines
[24].
These new approaches are encouraging because they
better reflect the current clinical scenario. In recent years, the
importance of detecting EGFR “expression” as a predictive
biomarker to discriminate between patients responding and
not responding to anti-EGFR drugs has lost its significance
for various reasons [30, 31]. It is well known that EGFR
inhibitors have clinical activity irrespective of total EGFR
quantity. For example, there is accumulating evidence of the
value of EGFR mutations in lung cancer and of k-ras
mutations in codons 12 and 13 in colorectal cancer as
predictive markers of sensitivity to anti-EGFR treatment
[31–33].
Thus, this approach should also be considered in
molecular imaging research, with more attention paid to
imaging receptor “function” which is influenced by muta-
tions or an aberrant downstream signaling pathway [34]. A
recent study identified distinct biological features underlying
the various EGFR mutations in nonsmall-cell lung cancer
(NSCLC) that may confer different transforming potential or
TK activity and consequently different sensitivity to EGFR
inhibitors [35]. Specific chemical structures of the tracers
and animal models should be developed to improve the
imaging of EGFR status in cancer. Developing PET probes
for imaging membrane receptors may have more rationale in
cases of receptor amplification, such as HER-2 in breast
cancer.
A remaining question is: if molecular predictive markers
are available in everyday practice, why still study EGFR
imaging? In vivo detection of EGFR may overcome several
limitations of tissue specimen analysis [36]. Firstly, the
information yielded by analysis of small tissue specimens
may not be representative of the whole tumor or all
metastases. Secondly, biological changes may occur during
the natural history of metastatic disease especially in long
survival or heavily pretreated patients. Lastly, invasive,
nonrepeatable, and time-consuming procedures are required
for both patients and physicians. As a consequence, the in
vivo and noninvasive detection of EGFR function with a
repeatable approach during disease progression may still
represent a major potential tool for many oncologists.
Conclusions
PEG-anilinoquinazoline tracers should be investigated in
animal models with an aberrant receptor function such as
Fig. 7. Total EGFR and ratio of activated (pY1068) EGFR protein level quantification by ELISA in U87MG (EGFR+) and
U138MG (EGFR−) masses.
M. A. Pantaleo, et al.: Molecular Imaging of EGFR in Cancer 623EGFRvIII mutants and HCC827 NSCLC models. Moreover,
novel chemical modifications are warranted to further
improve binding with the ATP pocket of the mutated kinase
domain underlying receptor activity. Lastly, it would also be
interesting to use an imaging approach to identify changes
related to the downstream signaling pathway of EGFR.
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